Demonstrates improved lipid metabolism and reduced inflammation in gout arthritis, suggesting HQC's potential as a treatment.
HQC inhibited inflammation and improved lipid metabolism in GA via inactivation of the IL-17 pathway by regulating m6A modification of lncRNA H19. Our findings further support the great potential of HQC as a candidate drug for GA treatment.
No takes yet. Share an insight, caveat, or question.
ZHANG et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: